Compumedics Sees Fiscal Year 2026 EBITDA of Up to AU$7 Million
Compumedics (ASX:CMP) said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$5.5 million to AU$7 million, according to a Tuesday Australian bourse filing.The company expects full fiscal year revenue of about AU$62 million to AU$65 million, representing growth of about 22% to 28% in fiscal year 2025.The company said liquidity has been strengthened with material magnetoencephalography (MEG) cash receipts in the fiscal third quarter and expanded working capital facilities providing AU$10 million to AU$11 million of available headroom.Revenue conversion has been impacted by timing factors, including MEG installation scheduling delays associated with conflict-related disruption in the Middle East affecting helium availability and pricing, as well as the deliberate prioritization of manufacturing readiness for Somfit D ahead of its full commercial rollout, the filing added.The company's shares rose 1% in recent Tuesday trade.
